Please check your internet connection and try again.
## Ecospirin (Aspirin) Enteric-Coated
### Overview
Ecospirin is an enteric-coated formulation of aspirin, a nonsteroidal anti-inflammatory drug (NSAID) belonging to the salicylate class. The enteric coating is designed to prevent dissolution in the stomach and delay absorption until the small intestine, potentially reducing gastric irritation.
### Primary Indications
* **Cardiovascular Protection:** Prevention of myocardial infarction, stroke, and cardiovascular death in patients with established cardiovascular disease or risk factors.
* **Analgesia and Antipyresis:** Relief of mild to moderate pain and fever.
* **Anti-inflammatory:** Reduction of inflammation in conditions like rheumatoid arthritis and osteoarthritis.
### Adult Dosing
* **Cardiovascular Protection:**
* **Primary Prevention:** Typically 75 mg to 100 mg once daily. Lower doses (e.g., 81 mg) are also commonly used.
* **Secondary Prevention:** Typically 75 mg to 325 mg once daily. Higher doses (e.g., 325 mg) may be used initially post-MI or stroke, then reduced to a lower maintenance dose.
* The specific dose for cardiovascular protection should be guided by patient risk factors and clinical guidelines.
* **Analgesia and Antipyresis:** 325 mg to 650 mg every 4 to 6 hours as needed. Maximum daily dose: 4000 mg.
* **Anti-inflammatory:** 2400 mg to 3600 mg daily in divided doses every 4 to 6 hours. May require doses up to 4800 mg to 7200 mg daily in divided doses for severe conditions, under strict medical supervision.
### Pediatric Dosing
Aspirin is generally **not recommended** for use in children and adolescents (<19 years) due to the risk of Reye's syndrome, particularly during viral illnesses like influenza or varicella. If aspirin is absolutely indicated, dosing should be based on specific guidelines and under strict medical supervision.
### Dose Adjustments
* **Renal Impairment:** Use with caution. Dose reduction may be necessary in severe renal impairment.
* **Hepatic Impairment:** Use with caution. Dose reduction may be necessary in severe hepatic impairment.
### Contraindications
* Hypersensitivity to aspirin, NSAIDs, or any component of the formulation.
* History of bronchospasm, asthma, urticaria, or allergic-type reactions after aspirin or NSAIDs.
* Active peptic ulceration or gastrointestinal bleeding.
* Children and adolescents with viral infections due to the risk of Reye's syndrome.
* Severe hepatic or renal impairment.
* Bleeding disorders.
### Adverse Effects
* **Gastrointestinal:** Dyspepsia, heartburn, nausea, vomiting, abdominal pain, occult bleeding, peptic ulceration, perforation, and hemorrhage.
* **Hematologic:** Increased bleeding time, bruising, petechiae, epistaxis, purpura.
* **Hypersensitivity:** Bronchospasm, urticaria, angioedema, anaphylaxis.
* **Auditory:** Tinnitus, hearing loss (especially with higher doses).
* **Renal:** Renal insufficiency, interstitial nephritis.
* **Hepatic:** Hepatotoxicity.
* **Reye's Syndrome:** In children and adolescents.
### Key Drug Interactions
* **Anticoagulants (e.g., warfarin, heparin, DOACs):** Increased risk of bleeding.
* **Other NSAIDs and COX-2 Inhibitors:** Increased risk of GI toxicity, bleeding, and renal impairment.
* **Corticosteroids:** Increased risk of GI ulceration and bleeding.
* **Antihypertensives (e.g., ACE inhibitors, ARBs, beta-blockers):** Reduced antihypertensive effect.
* **Diuretics:** Reduced diuretic and antihypertensive effect; increased risk of renal impairment.
* **Methotrexate:** Increased methotrexate toxicity.
* **Uricosuric agents (e.g., probenecid):** Reduced efficacy.
* **Selective Serotonin Reuptake Inhibitors (SSRIs):** Increased risk of bleeding.
* **Alcohol:** Increased risk of GI bleeding.
### Monitoring
* **Signs and symptoms of GI bleeding:** Melena, hematemesis, abdominal pain.
* **Bleeding time and signs of excessive bleeding:** Especially in patients on concomitant anticoagulants or with risk factors.
* **Renal and hepatic function:** Particularly in patients with pre-existing impairment or those on long-term therapy.
* **Tinnitus and hearing:** May indicate toxicity.
### Clinical Pearls
* The enteric coating is intended to delay absorption and reduce gastric irritation; however, it does not eliminate the risk of GI bleeding or ulceration.
* Do not crush or chew enteric-coated tablets.
* For cardiovascular protection, consistent daily dosing is crucial.
* Patients with asthma, nasal polyps, and aspirin sensitivity are at higher risk for severe reactions.
* Discontinue aspirin at least 7 days prior to elective surgery, if possible.
***
*Disclaimer: This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant clinical guidelines for complete and up-to-date details before making any treatment decisions.*
